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a b s t r a c t
The synthesis and spectroscopic characterization (UV–Vis, IR, EPR) of a new copper complex with a beta-
blocker propranolol (1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol) are presented. Besides, the X-
ray crystal structure of [Cu(propranolol)2]2H2O is determined, showing two different copper ions, one
coordinated through two S propranolol isomers and the other through two R isomers. The effect on
the heart contraction force and on the heart rate plus the block of response to adrenaline of the complex
and the free ligand, were studied. The effect of [Cu(propranolol)2]2H2O on contractility was very similar
to that of the free propranolol while the reduction on the heart rate is approximately 30% of the reduction
obtained with the free ligand. This is an encouraging result since the search of new beta-blocker drugs
that have lesser effect on heart rate is one of the important topics in cardiac pharmacology. The block
of the response to adrenaline is at least similar for both ligand and complex.
 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Beta-blockers represent a cornerstone for treatment of many
cardiovascular diseases. They are particularly useful for hyperten-
sion, arrhythmias and secondary myocardial protection after
infarction. Their actions are mediated by the blockade of beta-
receptors of the sympathetic branch of the autonomic nervous sys-
tem. Through this blockade beta-blockers reduce the frequency of
heart beat, lessen the force with which the heart muscle contracts
and reduce contraction of the blood vessel wall [1].
In several cases the activity over both the frequency and the
heart beat can complicate the therapy. It is known that one goal
for the treatment of ischemic disease and heart failure is the reduc-
tion of heart rate. Nevertheless, in many cases the beneﬁts of the
use of beta-blockers is counterbalanced by the reduction of the
heart rate. This is the case of patients with sick sinus, or partial
atrioventricular conduction defects, in such a cases beta-antago-
nists may cause life-threatening bradyarrhythmias [2,3].
In a meta-analysis over ﬁve trials and 8215 patients Ko et al. [4]
reported that one reason for withdrawal of beta-blocker therapy
could be the development of bradycardia.
Besides, it has been reported that in patients with chronic heart
failure (associated in many of them with coronary disease),
beneﬁts of beta-blocker therapy are independent from reduction
of heart rate [5].
For these reasons, the development of new drugs that present
independent action over the heart contraction force and the heart
rate is one of the important topics for cardiac research. Recently, a
novel drug ivabradine has been promoted in the market as the ﬁrst
treatment to reduce heart rate exclusively. Conversely, in this work
we are presenting one new complex that affects the hearth rate but
not the frequency.
Propranolol (Scheme 1) was the ﬁrst clinically useful beta
adrenergic receptor antagonist.
It is a non-selective beta-blocker, that is, it blocks the action of
adrenaline on both b1- and b2-adrenergic receptors. It has little
intrinsic sympathomimetic activity but has strong membrane sta-
bilizing activity [1].
On the other hand copper has been related with cardiovascular
diseases. For instance, copper deﬁcient diets, in animals, have pro-
duced structural and functional changes like aortic ﬁssures and
ruptures, arterial foam cells and smooth muscle migration, coro-
nary artery thrombosis, glucose intolerance, elevation of serum
cholesterol and hypertension [6]. Besides, copper depletion exper-
iments with men and women have revealed abnormalities of lipid
metabolism and blood pressure control [7–9].
For these reasons a strategy for obtaining new drugs with better
cardiac performance might be to study new complex species where
both components ligand and metal have cardiovascular effects.
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There are antecedents that the complexation of several drugs
with copper ions caused changes in the pharmacological and phys-
iological effects. For instance, copper complex of pindolol has
shown higher efﬁciency than the free ligand regarding its effect
on the heart rate of rats [10]. Besides, in the literature reports of
several copper complexes with beta-blocker antihypertensive
drugs can be found [11,12] but only a few X-ray crystallographic
structures have been reported [10,13,14] and none of them with
propranolol.
Due to these antecedents and in order to continue our studies
on medicinal chemistry [15–17], our aim was to obtain copper
beta-blocker complexes in the search of new species with better
pharmacological properties and/or that will provide biological
information.
In this work, the synthesis and spectroscopic characterization of
a new copper complex with propranolol (1-(isopropylamino)-3-
(1-naphthyloxy)-2-propanol) are presented.
Fig. 1 shows the structure of propranolol, showing the amino
and hydroxyl groups suitable for coordination of metal ions.
First of all we studied the structure in solid state. The X-ray
crystal structure of [Cu(propranolol)2]2H2O was determined and
the IR and EPR spectra were analyzed. Besides, this work is the ﬁrst
that reports the chirality of the beta-blocker ligands coordinated to
copper. This is an important datum for understanding the pharma-
cological properties due to the fact that the enantioselectivity
inﬂuences the pharmacokinetics of these drugs and also it is asso-
ciated with changes in the pharmacodynamic proﬁle [18].
The structural information in solid state was used as a base for
the characterization of the species in DMSO solution that will be
administered in the biological assays. Besides, the stability of this
solution was studied. Moreover, an analysis of the effect on the
contraction force and heart rate, and the block of response to
adrenaline were performed.
2. Experimental
2.1. Synthesis of the complex and analytical characterization
Aqueous solutions of dl-propranolol hydrochloride (1 mmol,
0.295 g), SIGMA and of CuSO45H2O (0.5 mmol, 0.085 g), FLUKA
were mixed. After stirring 1 mL of 1 M NaOH was added. Upon
mixture a violet precipitate was formed. It was washed with water
and recrystallized from methanol. The violet crystals obtained
were separated by ﬁltration and dried at room-temperature.
The elemental analysis was performed with a Carlo Erba
EA1108 elemental analyzer and copper content was determined
by iodimetry.
Anal. Calc. for [Cu(propranolol)2]2H2O (C32H44N2O6Cu): C,
62.37; N, 4.55; H, 7.20; Cu, 10.31. Found: C, 62.00; N, 4.44; H,
7.11; Cu, 10.31. Yield 38%.
2.2. Crystal structure determination of [Cu(propranolol)2]2H2O
Room temperature X-ray diffraction data collection for [Cu(pro-
pranolol)2]2H2O was performed on an Enraf-Nonius Kappa-CCD
diffractometer, using graphite-monochromated Mo Ka radiation
(0.71073 Å). Data were collected up to 50.0 in 2. The ﬁnal unit cell
parameters were based on all reﬂections. Data collections were
made using the COLLECT program [19]. Integration and scaling of
the reﬂections were performed with the HKL Denzo–Scalepack sys-
tem of programs [20]. Multi-scan absorption corrections were ap-
plied [21].
The structure was solved by direct methods with SHELXS-97 [22].
The model was reﬁned by full-matrix least-squares on F2 with
SHELXL-97 [23]. All the hydrogen atoms were stereochemically posi-
tioned and reﬁned with the riding model [23]. Data collections and
experimental details for the complexes are summarized in Table 1.
The programs SHELXL-97, and ORTEP-3 [24] were used within WINGX
[25].
2.3. Spectroscopic measurements
Electronic spectrum of a DMSO solution was registered on a
Milton Roy Spectronic 3000 spectrophotometer.
Low-temperature (77 K) EPR experiments were performed
using a Varian E109 spectrometer equipped with a rectangular cav-
ity. To perform the experiments on solution-state samples, powder
samples of the titled complexes were dissolved in DMSO. The solu-
tion-state samples were then centrifuged, and the supernatants
were drawn in a quartz sample tube for low-temperature EPR
experiments. General experimental conditions were: microwave
power, 20 mW; modulation amplitude, 2.0 G; modulation fre-
quency, 100 kHz. The g- and A-values were obtained by means of
spectral simulation using the software package EASYSPIN [26].
IR spectra, in the range between 4000 and 200 cm1, were re-
corded on a BOMEM M 102 FTIR spectrophotometer using the
KBr pellet technique.
OH
ONH
Fig. 1. Scheme of propranolol.
Table 1
Crystal data and structure reﬁnement of complex [Cu(propranolol)2]2H2O.
Empirical formula C32H44N2O6Cu
Formula weight 616.23
Temperature (K) 293(2)
Wavelength (Å) 0.71073
Crystal system triclinic
Space group P1
Unit cell dimensions
a = 8.472(1) Å a = 90.24(1)
b = 12.057(2) Å b = 98.94(1)
c = 15.449(2) Å c = 91.548(6)
V 1558.3(4) Å3
Z 2
Dcalc (Mg/m3) 1.313
Absorption coefﬁcient (mm1) 0.746
F (0 0 0) 654
Crystal size (mm3) 0.15  0.10  0.02
Theta range for data collection 2.92–25.00
Index ranges 10 6 h 6 9, 14 6 k 6 14,
17 6 l 6 18
Reﬂections collected 7417
Independent reﬂections 4963 [R(int) = 0.1269]
Completeness to h = 22.00 95.6%
Absorption correction Semi-empirical from equivalents
Maximum and minimum transmission 0.984 and 0.865
Reﬁnement method Full-matrix least-squares on F2
Computinga COLLECT, HKL Denzo and Scalepack
SHELXS-97, SHELXL-97
Data/restraints/parameters 4963/0/374
Goodness-of-ﬁt (GOF) on F2 1.008
Final R indices [I > 2r(I)] R1 = 0.0784, wR2 = 0.1480
R indices (all data) R1 = 0.2017, wR2 = 0.2019
Largest differences in peak and hole
(e Å3)
0.259 and 0.334
a Data collection, data processing, structure solution and structure reﬁnement
respectively.
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2.4. Thermogravimetric measurements
Thermogravimetric measurements were obtained with a Shi-
madzu TGA 50 thermobalance, with a platinum cell, working under
ﬂowing air (50 mL min1) and at a heating rate of 6 C min1.
2.5. Stability tests
Conductimetric measurements using a Conductivity Meter
4310 Jenway were performed at 37 C in a DMSO solution (0.5 
103 M). Besides, the DMSO solution was mixed (1:10) with Tyrode
solution and the absence of turbidity was observed. Both tests
were performed with the aim of studying the stability of the com-
plex in the solution that was administered in the biological studies.
2.6. Biological evaluation by Langendorff technique
The biological evaluation of the complex and the free ligand was
performed using an isolated heart technique according to Lange-
ndorff [27].
Guinea pigs weighing 400–600 g were heparinized (1000 UI/kg)
10 min before the procedure. Then they were anaesthetized with a
sodium pentothal intraperitoneal injection (50 mg/kg).
The hearts were rapidly removed and placed into a dish con-
taining oxygenated Tyrode solution (see composition below) at
room-temperature. The aorta was cannulated and the heart was
perfused retrogradely via the aortic cannula, at a constant ﬂow rate
of 6 mL min1 with Tyrode solution containing: NaCl 137, KCl 2.68,
MgCl2 1.05, NaHCO3 12, CaCl2 1.8, NaH2PO4 0.38, glucosa 5.5 nM.
By means of Langendorff equipment the perfusate was kept at
36 ± 1 C. Solution was aerated with a gas mixture of 95% of O2
and 5% of CO2 in order to obtain a pH of 7.4. Myocardial contractile
force was evaluated measuring the left ventricular pressure. The
left atrial appendage was removed to access to the mitral valve ori-
ﬁce, a small hand-made latex balloon was inserted through it, and
placed into the left ventricular cavity. The balloon previously ﬁlled
with saline solution was connected to a pressure transducer (Sta-
tham) by means of a catheter. The manometer was connected to
a suitable ampliﬁer, and the signals were fed into a digital to ana-
log converter device (Lab Master). Finally signals were displayed
and stored into a computer. The basal conditions were controlled
and the experiments were started after the parameters reached a
steady state.
The protocol followed for the determination of the effect on
contraction force and heart rate was the following:
A bolus of 0.1 mL of propranolol solution in DMSO (103 M,
n = 5) or 0.1 mL of [Cu(propranolol)2]2H2O solution in DMSO
(0.5  103 M, n = 5) was administered, both equimolar solutions
in propranolol. The contraction force and heart rate were measured
before and after administration.
The protocol followed for the determination of the inhibition of
response to adrenaline was the following:
The heart was stimulated with a bolus of 0.1 mL of adrenaline
30 M injected through the side branch of the perfusion cannula.
The response in terms of contraction force and heart rate was mea-
sured. After this stimulation, the heart was washed and stabilized
with the perfusion solution for 15 min. Then a bolus of 0.1 mL of
propranolol solution
(103 M, n = 5) or 0.1 mL of [Cu(propranolol)2] 2H2O solution
(0.5  103 M, n = 4), was administered and the heart was stabi-
lized during 4 min. Finally, a similar dose of adrenaline was in-
jected and the response was measured and compared with the
ﬁrst stimulation.
Controls with bolus of Tyrode, DMSO and with copper salt dis-
solved in DMSO were performed in both protocols.
3. Results and discussion
3.1. Crystal structure of [Cu(propranolol)2].2H2O
The copper complex crystallized in a triclinic system with a P1
spatial group as shown Table 1.
The structure consists of two units, each containing a copper
center coordinated to two deprotonated propranolol molecules
acting as a bidentate ligand, in a distorted square-based environ-
ment. Fig. 2 presents an ORTEP view of a unit, showing the atom la-
bels and 50% probability ellipsoids. As Fig. 2 shows each copper ion
coordinates through the N atom from the amine group and the O
atom from the alkoxide, in a trans geometry.
The crystal structure is completed with the presence of two
hydration water molecules per complex. Selected bond distances
and angles around the copper center are summarized in Table 2.
In comparison with related copper compounds, Cu–Oalcohol dis-
tances found in this work (1.874 and 1.894 Å) are shorter than
those of the Cu(II) complex with nadolol (1.910 Å) [28], with etile-
frin (Effortil) (1.905 Å) [29], with propafenone (1900 Å) [30] and
clenbuterol (1898 Å) [31] and for one of the Cu–O bonds from
the Cu(II) complex with oxprenolol (1.909 Å) [13]. In the case of
Cu–Namine distances (2.020 and 2.033 Å) the results are similar to
those reported for the compounds mentioned above. The dihedral
angle between the planes determined by O11–N1–Cu and O21–
N2–Cu is 20.5(3), showing the distortion of the arrangement.
The centrosymmetry of the space group found in this work re-
quires that both the R,R and S,S complexes be present. This new
complex presents different propranolol isomers coordinated to
each copper ion. As it is known propranolol has one chiral carbon
Fig. 2. ORTEP view of one unit of the complex, showing the atom labeling and the 50%
probability ellipsoids.
Table 2
Selected bond lengths [Å] and angles [] of complex [Cu(propranolol)2]2H2O.
Cu–O(21) 1.874(5)
Cu–O(11) 1.894(5)
Cu–N(2) 2.020(6)
Cu–N(1) 2.033(6)
O(21)–Cu–O(11) 166.8(3) C(105)–O(11)–Cu 111.6(4)
O(21)–Cu–N(2) 85.5(3) C(205)–O(21)–Cu 113.9(5)
O(11)–Cu–N(2) 97.0(2) C(103)–N(1)–Cu 117.6(5)
O(21)–Cu–N(1) 94.3(2) C(104)–N(1)–Cu 104.1(4)
O(11)–Cu–N(1) 86.5(2) C(204)–N(2)–Cu 104.6(4)
N(2)–Cu–N(1) 165.3(3) C(202)–N(2)–Cu 115.2(5)
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atom and it can form two enantiomers. The usual pharmaceutical
formulations are prepared with the racemic mixture. In the synthe-
sis of [Cu(propranolol)2]2H2O a racemic mixture of propranolol
was used but as Fig. 3 shows, each copper unit in the obtained
structure coordinates with the same isomer, and the compound
could be better described as [Cu(R-propranololate)2][Cu(S-
propranololate)2]4H2O.
No report of the coordinated isomers was found in the previ-
ously referred articles related to copper complexes with beta-
blockers.
The study of the crystal packing shows that the three-dimen-
sional structure is stabilized by six intermolecular hydrogen bonds
as shown in Table 3.
All these intermolecular interactions give rise to the formation
of double inﬁnite chains and layers of complex molecules alternate
with layers of water molecules (see Fig. 4).
This particular crystal packing, with its water channels could be
important for pharmacotechnic processes.
3.2. Thermogravimetric measurements
Thermogravimetric results showed that the weight loss at 50–
85 C range was 6%, in accordance with the release of two hydra-
tion water molecules. Beyond 230 C the degradation of the ligand
was observed.
3.3. Stability tests
The conductivity of a DMSO solution of [Cu(propranolol)2]2H2O
was very similar to that of the pure solvent. This behavior is in
agreement with the neutral charge of the complex, according to
the stoichiometry. In addition, the conductivity was measured dur-
ing 24 h and no major changes were observed. This result showed
that the complex maintained the neutral charge and therefore the
Cu–propranolol bonds remained in the structure in solution. Be-
sides, when the DMSO solution of the complex was mixed with
the Tyrode solution no turbidity was observed. Taking into account
that the propranolol is insoluble in this solution, this result shows
that the propranolol is not free.
3.4. Spectroscopic measurements
The electronic spectrum of [Cu(propranolol)2]2H2O in DMSO
presented one broad band at 685 nm, due to the d–d band transi-
tion. This result is in agreement with the reported data for the
square planar CuN2O2 chromophore [32]. The substitution of the
propranolol molecules by DMSO is not observed since the spec-
trum of copper sulfate in DMSO shows a kmax = 813 nm.
Low-temperature X-band EPR spectra of the titled compound in
the polycrystalline form displayed a single resonance around
330 mT (Fig. 6A) with no detectable hyperﬁne interaction be-
tween the magnetic moments of the S = 1/2 d9 copper unpaired
electron and of the I = 3/2 copper nuclear spin. The powder-like
spectra is characteristic of monomeric species interacting via weak
superexchange interactions, which smear out the hyperﬁne lines,
and are probablymediated by non-covalent bridges as is usually ob-
served in copper complexes in the solid state [33,34]. Simulation of
that spectrum yielded g-values: gx = gy = 2.0407 (perpendicular
direction) and gz= 2.1312 (parallel direction), thus indicating an axi-
ally symmetric environment experienced by the copper ion, which
is in good agreement with the structural data presented above.
Upon dilution in DMSO solvent, EPR spectra of the compound at
liquid nitrogen temperature readily showed the four hyperﬁne
Fig. 3. View of the structure cell showing the S (A) and R (B) propranololate isomers coordinated with copper ions.
Table 3
Intermolecular interaction geometry (ÅA
0
,) of [Cu(propranolol)2]H2O.
D–H   D–H D  A H  A D–H  A
O1w–H11w  O2w 0.850 2.789(7) 1.971 161.2(4)
O1w–H12w  O2wi 0.850 2.766(7) 1.944 162.5(4)
N1–H1  O1wii 0.910 2.975(9) 2.075 169.5(5)
N2–H2   O1wiii 0.910 3.036(9) 2.194 153.7(5)
O2w–H21w  O21ii 0.982 2.651(8) 1.738 153.1(4)
O2w–H22w  O11iv 0.979 2.678(7) 1.715 166.9(4)
Symmetry codes: (i) x + 1, y + 2, z; (ii) x + 1,y + 1, z; (iii) x  1, y  1, z; (iv)
x + 1, y + 1, z.
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lines (Fig. 6B) characteristic of a S = 1/2 spin system interacting
with I = 3/2 nuclear spin. The appearance of hyperﬁne structure
suggests that the connections supporting exchange interactions
in the solid state are disrupted upon dilution in DMSO, indicating
that those connections are not provided by covalent bonds be-
tween monomers. To further characterize this spectrum, theoreti-
cal simulation was performed using the software EASYSPIN. The
simulation involved the use of a spin Hamiltonian constituted by
Zeeman and hyperﬁne interactions along with two linewidth
parameters that take care of extra broadening mechanisms. The ﬁ-
nal calculated spectrum showed a very good agreement with the
experimental data and the best-ﬁt magnetic parameters (g and
hyperﬁne) thus determined were: gx = 2.059, gy = 2.025, gz =
2.200, Az = 19.2 mT. The values of the Ax and Ay components could
not be determined since the spectrum does not show any splitting
due to those components. The gz and Az values can be used to
determine the atoms coordinated to the copper ion following the
method of Peisach that correlate those values with the coordina-
tion sphere of copper in several complexes [35]. In our case, the
values of gz and Az indicate a N2O2 equatorial coordination that
agrees with the X-ray single-crystal data presented above. Thus,
in solution the copper environment is distorted from its solid state
axial symmetry, without changes in atoms coordinated (it is main-
tained with two nitrogen and two oxygen atoms).
To investigate the structural stability of the compound after
dilution in DMSO, we also performed a low-temperature EPR
experiment on a sample after 24 h of dilution in DMSO. The spec-
trum is shown in Fig. 5C and shows no major difference when com-
pared with the spectrum measured right after mixture with DMSO
(Fig. 5B). The simulation of this last spectrum resulted in the same
set of magnetic parameters except for the line widths parameters,
which had to be readjusted to achieve optimal ﬁtting of the exper-
imental data. This strongly suggests that the structure of the com-
pound is stable without major difference 24 h after dilution in
DMSO.
Fig. 4. Crystal packing of [Cu(propranolol)2]2H2O along c-axis.
240 280 320 360
 Experimental
 Calculated
Magnetic field (mT)
(C)
(A)
(B)
Fig. 5. Low-temperature X-band EPR spectra of [Cu(propranolol)2]2H2O in: (A)
solid state, (B) fresh DMSO solution and (C) DMSO solution after 24 h of the dilution
experimental and calculated spectra are shown as black and red lines, respectively.
(For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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The IR spectrum of the complex was compared with that of the
free propranolol and the similar reported complexes [14,36–39].
The free ligand spectrum exhibits three strong bands at 3323,
3281 and 3227 cm1 corresponding to the m(OH), ma(–NHþ2 –) and
ms(–NHþ2 –) engaged in H-bonds. In addition, combination bands,
enhanced by Fermi resonance, are found in the range 2710–
2395 cm1 [14,36,38]. The NH2+ deformation band is overlapped
by the aromatic bands.
After coordination the –NHþ2 – is deprotonated and a band at
3377 cm1 is observed in the complex spectrum in agreement with
bibliographic data [36]. Furthermore the disappearance of the
bands due to the combination modes, which is characteristic of
the protonated amines, is also in agreement with the coordination
through this group.
Regarding OH group, in the complex spectrum there is one less
band in the range assigned to m(OH) and m(–NHþ2 –) engaged in H-
bonds, due to the deprotonation of this group upon coordination,
and the band at 1324 cm1 in the free ligand, corresponding to
r(HC–OH) shifts to 1312 cm1 upon complexation. This behavior
supports the coordination through this group. Further evidence
of this is found in the fact that the m(C–O) band of the ligand at
1107 cm1 shifts to 1098 cm1 [36].
Another observation in the complex spectrum is the appearance
of new bands at 604 cm1 and 497 cm1, assigned to Cu–N and Cu–
O bonds respectively, in accordance with bibliographic data [14].
3.5. Biological evaluation
3.5.1. Determination of the effect on contraction force and heart rate
Fig. 6 shows the effect of the administration of propranolol
(103 M), [Cu(propranolol)2]2H2O (0.5  103 M) and copper salt
(0.5  103 M) on myocardial contractile force and heart rate.
As can be seen in Fig. 7A the effect of propranolol and [Cu(pro-
pranolol)2]2H2O on myocardial contractile force is to reduce it to a
rather similar extent. On the other hand, both complex and free li-
gand reduced heart rate but the reduction obtained with the com-
plex is lower than that obtained with the free ligand, as shown in
Fig. 7B. The reduction on the heart rate performed by the complex
is approximately 30% of that produced by the free ligand.
The controls performed with DMSO and Tyrode did not signiﬁ-
cantly change the signals. On the contrary, the bolus of Cu(II) salt
produced a slight increase both in myocardial contractile force
and heart rate, which differs from the copper complex’s effect.
3.5.2. Determination of inhibition of response to adrenaline
Fig. 7 shows that both species block the response to adrenaline
to a similar extent when contractility is measured. Adrenaline’s ef-
fect on heart rate was blocked by either complex or ligand at the
dose used.
The control performed with Cu(II) salt (0.5  103 M), produced
a much lesser blockade when contractility was measured.
4. Conclusions
A new Cu–propranolol complex was synthesized and character-
ized by spectroscopic measurements including X-ray diffraction.
Specially the chirality of this new complex was observed showing
that the compound could be better described as [Cu(R-propranolo-
late)2][Cu(S-propranololate)2]4H2O. Besides, in accordance with
the conductivity assay, the electronic spectrum, the propranolol is
still coordinates with copper ion in a 103 M DMSO solution. The
magnitude of Az and gz obtained from the EPR spectra indicated that
Cu is equatorially coordinated through two nitrogen and two oxygen
atoms. These structural data in solution agree with the X-ray single-
crystal data. In addition, the conductivitymeasurements and the EPR
spectra showed that this solution is stable at least during 24 h.
About the biological assay, the effect of [Cu(propranolol)2]2H2O
on contractility was very similar to that of the free propranolol
while the reduction on the heart rate is approximately 30% of that
of the free ligand. The block of the response to adrenaline is at least
similar for both ligand and complex. Therefore we obtained a new
complex that affects specially the contractility and to a minor ex-
tent the heart rate.
The results are certainly encouraging due to the fact that the
search for new beta-blocker drugs that have lesser effect on heart
rate is one of the important topics in cardiac pharmacology.
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Fig. 6. Effect of bolus of [Cu(propranolol)2]2H2O (0.5  103 M), propranolol (103 M) and copper salt (0.5  103 M) on myocardial contractile force (A) and heart rate (B).
Fig. 7. Percentage of blockade of the complex (0.5  103 M), free propranolol
(103 M) and copper salt (0.5  103 M) measuring the response as variation in
myocardial contractile force.
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